{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:31Z","timestamp":1753891351110,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Anti-TIF-1\u03b3 autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1\u03b3 detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA\/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1\u03b3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebr\u00f3n Hospital (Barcelona, Spain) tested for anti-TIF-1\u03b3 autoantibodies using the Euroline profile and an in-house immunoblot assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 27 anti-TIF-1\u03b3 were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen\u2019s kappa 0.3163. Expected prevalence of anti-TIF-1\u03b3 autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1\u03b3 autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p&amp;lt;0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1\u03b3 antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We recommend using a second validated method to confirm Euroline-detected anti-TIF-1\u03b3 antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1\u03b3 antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.625896","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T05:54:53Z","timestamp":1612158893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-TIF-1\u03b3 Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice"],"prefix":"10.3389","volume":"11","author":[{"given":"Ana\u00eds","family":"Mariscal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Mil\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Baucells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angeles","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Garcia","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Trallero-Aragu\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Alvarado-Cardenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Alserawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Franco-Leyva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Sanz-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vi\u00f1as-Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1ndido","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Selva-O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: An association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Trallero-Aragu\u00e1s","year":"2010","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Anti-TIF1\u00e3 antibodies (anti-p155) in adult patients with dermatomyositis: Comparison of different diagnostic assays","volume":"71","author":"Labrador-Horrillo","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket383","article-title":"Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation","volume":"53","author":"Aggarwal","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci [Internet]"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00848","article-title":"Comparison of three immunoassays for the detection of myositis specific antibodies","volume":"10","author":"Mahler","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"B15","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012595961-2\/50037-8","article-title":"Polymyositis and Dermatomyositis","volume":"13","author":"Hohlfeld","year":"2006","journal-title":"Autoimmune Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102107","article-title":"The New England Journal of Medicine Downloaded from nejm.org at University of Arizona on September 29, 2014. For personal use only. No other uses without permission. From the NEJM Archive. Copyright \u00a9 2010 Massachusetts Medical Society. All rights reserve","volume":"310","author":"Sheagren","year":"1984","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: A methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802687455","article-title":"Association of distinct clinical subsets with myositisspecific autoantibodies towards anti155\/140kDa polypeptides, anti-140-kDa polypeptides, and antiaminoacyl tRNA synthetases in Japanese patients with dermatomyositis: A singlecentre, crosssectional stud","volume":"38","author":"Fujikawa","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.625896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:29:48Z","timestamp":1612816188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.625896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2020.625896"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.625896","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"625896"}}